RT Journal Article
SR Electronic
T1 A sensitive and affordable multiplex RT-qPCR assay for SARS-CoV-2 detection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.14.20154005
DO 10.1101/2020.07.14.20154005
A1 Reijns, Martin A.M.
A1 Thompson, Louise
A1 Acosta, Juan Carlos
A1 Black, Holly A.
A1 Sanchez-Luque, Francisco J.
A1 Diamond, Austin
A1 Daniels, Alison
A1 O’Shea, Marie
A1 Uggenti, Carolina
A1 Sanchez, Maria C.
A1 McNab, Michelle L.L.
A1 Adamowicz, Martyna
A1 Friman, Elias T.
A1 Hurd, Toby
A1 Jarman, Edward J.
A1 Li Mow Chee, Frederic
A1 Rainger, Jacqueline K.
A1 Walker, Marion
A1 Drake, Camilla
A1 Longman, Dasa
A1 Mordstein, Christine
A1 Warlow, Sophie J.
A1 McKay, Stewart
A1 Slater, Louise
A1 Ansari, Morad
A1 Tomlinson, Ian P.M.
A1 Moore, David
A1 Wilkinson, Nadine
A1 Shepherd, Jill
A1 Templeton, Kate
A1 Johannessen, Ingolfur
A1 Tait-Burkard, Christine
A1 Haas, Jürgen G.
A1 Gilbert, Nick
A1 Adams, Ian R.
A1 Jackson, Andrew P.
YR 2020
UL http://medrxiv.org/content/early/2020/07/16/2020.07.14.20154005.abstract
AB With the ongoing COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, there is need for sensitive, specific and affordable diagnostic tests to identify infected individuals, not all of whom are symptomatic. The most sensitive test involves the detection of viral RNA using RT-qPCR, with many commercial kits now available for this purpose. However, these are expensive and supply of such kits in sufficient numbers cannot always be guaranteed. We therefore developed a multiplex assay using well-established SARS-CoV-2 targets alongside internal controls that monitor sample quality and nucleic acid extraction efficiency. Here, we establish that this test performs as well as widely used commercial assays, but at substantially reduced cost. Furthermore, we demonstrate >1,000-fold variability in material routinely collected by nose-and-throat swabbing. The inclusion of a human control probe in our assay provides additional information that could help reduce false negative rates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCT-B and MOS were funded by BBSRC Institute Strategic Programme grant funding (BBS/E/D/20002172, BBS/E/D/20002173). This work was supported by a UK Medical Research Council Human Genetics Unit core grant (MRC, U127580972) and by NHS National Services Scotland, as part of a technology development exercise at the NHS-led University of Edinburgh/NHS Lothian COVID-19 testing centre at the Institute of Genetics and Molecular Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Tissue Governance for the South East Scotland Scottish Academic Health Sciences Collaboration Human Annotated BioResourceAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesn/a